Functional (psychogenic) movement disorders (FMD) constitute a cluster of heterogeneous diagnoses involving motor symptoms that cannot be explained by organic pathology and are often associated with underlying psychological problems. In psychiatry, patients with FMD are often placed within the scope of somatoform disorders and conversion disorders. Functional Parkinsonism (FP) is a rare form of FMD seen in 1.5% of all patients presenting with symptoms of parkinsonism. Although almost all symptoms of parkinsonism can be present in FP, clinical features such as sudden onset and a nonprogressive course, inconsistent response to pharmacotherapy, and atypical findings in neurological examination are considered as important clues of psychogenic aetiology. Limited data in the literature on FP indicate that the average age of onset is between 37-53 years of age, whereas the average onset age of Idiopathic Parkinson's Disease (IPD) is around 60; and Juvenile Parkinsonism, a rare condition presenting before the age of 21, is often familial and more closely related to genetic mutations. Here, we present the case of a female patient, who, after the diagnosis of Juvenile Parkinsonism at the age of 17, had been treated with antiparkinsonian medications for about 14 years in the neurology clinic. Even though the age of onset of this case was far earlier than expected for both IPD and FP and the symptoms became chronic despite close monitoring, it is believed that this case is a striking example for the importance of the recognition of FP and early intervention.

Download full-text PDF

Source
http://dx.doi.org/10.5080/u25540DOI Listing

Publication Analysis

Top Keywords

juvenile parkinsonism
12
functional parkinsonism
8
diagnosis juvenile
8
parkinsonism rare
8
symptoms parkinsonism
8
age onset
8
parkinsonism
7
age
6
case
4
case chronic
4

Similar Publications

The smoking cessation drug cytisine exerts neuroprotection in substantia nigra pars compacta (SNc) dopaminergic (DA) neurons of female but not male 6-hydroxydopamine (6-OHDA) lesioned parkinsonian mice. To address the important question of whether circulating 17β-estradiol mediates this effect, we employ two mouse models aimed at depleting systemically circulating 17β-estradiol: (i) bilateral ovariectomy (OVX), and (ii) aromatase inhibition with systemically administered letrozole. In both models, depleting systemically circulating 17β-estradiol in female 6-OHDA lesioned parkinsonian mice results in the loss of cytisine-mediated neuroprotection as measured using apomorphine-induced contralateral rotations and SNc DA neurodegeneration.

View Article and Find Full Text PDF

Parkinson's Disease (PD) is a neurodegenerative disorder that is often accompanied by slowness of movement (bradykinesia) or gradual reduction in the frequency and amplitude of repetitive movement (hypokinesia). There is currently no cure for PD, but early detection and treatment can slow down its progression and lead to better treatment outcomes. Vision-based approaches have been proposed for the early detection of PD using gait.

View Article and Find Full Text PDF

Associations between frailty and cognitive impairment in Parkinson´s disease: a cross-sectional study.

Aging Clin Exp Res

January 2025

Instituto de Neurociencias del Principado de Asturias (INEUROPA), University of Oviedo, Oviedo, 33003, Spain.

Background: The presence of frailty is common in people with Parkinson's disease, as is cognitive dysfunction. Previous research on frailty has focused on the physical aspects of the pathology.

Aims: To analyze the relationship between frailty and cognitive impairment in patients with Parkinson's disease and to know which disease characteristics are associated with frailty.

View Article and Find Full Text PDF

Background And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life. Addressing such symptom burden, the 2023 revised "Parkinson's disease" guideline of the German Society of Neurology aimed at providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain and sleep disturbances.

Methods: Key PICO (Patient, Intervention, Comparison, Outcome) questions were formulated by the steering committee and refined by the assigned authors.

View Article and Find Full Text PDF

Background: Huntington's disease (HD) is an autosomal dominant condition causing severe neurodegeneration in the striatum and the entorhinal cortex (EC). An epigenome wide association study of DNA methylation in HD by our group, identified potential hypomethylation at the PTGDS gene in the striatum. We aimed to validate this result through pyrosequencing, examining the locus in fine detail, and to assess the signal specificity by profiling multiple neurodegenerative diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!